MX2018003179A - Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. - Google Patents
Terapia de combinación con cenicriviroc para el tratamiento de fibrosis.Info
- Publication number
- MX2018003179A MX2018003179A MX2018003179A MX2018003179A MX2018003179A MX 2018003179 A MX2018003179 A MX 2018003179A MX 2018003179 A MX2018003179 A MX 2018003179A MX 2018003179 A MX2018003179 A MX 2018003179A MX 2018003179 A MX2018003179 A MX 2018003179A
- Authority
- MX
- Mexico
- Prior art keywords
- cenicriviroc
- ppar
- agonist
- cvc
- fibrosis
- Prior art date
Links
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 title abstract 5
- 229950011033 cenicriviroc Drugs 0.000 title abstract 5
- 206010016654 Fibrosis Diseases 0.000 title abstract 2
- 230000004761 fibrosis Effects 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 abstract 2
- 101150023944 CXCR5 gene Proteins 0.000 abstract 2
- 102000012141 Peroxisome proliferator-activated receptor alpha Human genes 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 abstract 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 abstract 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 abstract 1
- 102000001326 Chemokine CCL4 Human genes 0.000 abstract 1
- 108010055165 Chemokine CCL4 Proteins 0.000 abstract 1
- 102000001327 Chemokine CCL5 Human genes 0.000 abstract 1
- 108010055166 Chemokine CCL5 Proteins 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- -1 MIP-1a Proteins 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7052—Fibrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
Abstract
El Cenicriviroc (CVC) es un antagonista oralmente activo de unión de ligando al receptor de quimiocina C-C tipo 5 (CCR5) y el receptor de quimiocina C-C de tipo 2 (CCR2). CVC bloquea la union de RANTES, MIP-1a, y MIP-1ß a CCR5, y de MCP-1/CCL2 a CCR2. Se proporcionan en la presente métodos para tratar la fibrosis y afecciones relacionadas, que comprenden la coadministración de CVC con antagonistas de FXR, vitamina E de dosis elevada (> 400 iU/d, un agonista del receptor alfa activado por el proliferador de peroxisoma (PPAR-a), agonista PPAR-?, agonista de PPAR-d y/o agonista de quimiocina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219356P | 2015-09-16 | 2015-09-16 | |
| PCT/US2016/022639 WO2017048322A1 (en) | 2015-09-16 | 2016-03-16 | Cenicriviroc combination therapy for the treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018003179A true MX2018003179A (es) | 2018-08-21 |
Family
ID=58289631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003179A MX2018003179A (es) | 2015-09-16 | 2016-03-16 | Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180360846A1 (es) |
| EP (1) | EP3349751A4 (es) |
| JP (1) | JP2018532720A (es) |
| KR (1) | KR20180088373A (es) |
| CN (1) | CN108289881A (es) |
| AU (1) | AU2016323468A1 (es) |
| BR (1) | BR112018005163A2 (es) |
| CA (1) | CA2998509A1 (es) |
| HK (1) | HK1258396A1 (es) |
| IL (1) | IL258002A (es) |
| MX (1) | MX2018003179A (es) |
| RU (1) | RU2018113437A (es) |
| SG (1) | SG10202002323UA (es) |
| WO (1) | WO2017048322A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| EP3149156B1 (en) | 2014-05-28 | 2021-02-17 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| JP6804438B2 (ja) | 2014-10-17 | 2020-12-23 | チルドレンズ ホスピタル メディカル センター | 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法 |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| EP3534976A4 (en) | 2016-11-04 | 2020-09-16 | Children's Hospital Medical Center | PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE |
| US20220362263A1 (en) * | 2016-11-10 | 2022-11-17 | Galmed Research And Development Ltd | Treatment for fibrosis and inhibition of fibrosis |
| JP2020500199A (ja) | 2016-11-21 | 2020-01-09 | バイキング・セラピューティクス・インコーポレイテッド | グリコーゲン蓄積症の治療方法 |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| AU2017386648A1 (en) * | 2016-12-28 | 2019-07-18 | Modunex Bio Corp. | Combination therapy for nonalcoholic steatohepatitis (NASH) and liver fibrosis |
| EA201991990A1 (ru) | 2017-02-24 | 2020-04-07 | Женфит | Фармацевтические композиции для комбинированной терапии |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EP3694603A4 (en) | 2017-10-10 | 2021-07-14 | Children's Hospital Medical Center | ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF |
| CN109806386A (zh) * | 2017-11-20 | 2019-05-28 | 江苏恒瑞医药股份有限公司 | Fxr激动剂与glp-1类似物的药物组合物和用途 |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| EP4467158A3 (en) * | 2018-02-14 | 2025-02-19 | Lumos Pharma, Inc. | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| WO2020006199A2 (en) | 2018-06-27 | 2020-01-02 | The Regents Of The University Of California | Methods and agents for modulating inflammation |
| KR102887406B1 (ko) | 2018-07-26 | 2025-11-19 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| WO2020056158A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US12458612B2 (en) * | 2019-04-10 | 2025-11-04 | Genfit | Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists |
| CN110559297B (zh) * | 2019-09-09 | 2023-03-17 | 中山大学 | 咪唑并吡啶类化合物在制备抗黄病毒属病毒感染试剂或药物中的应用 |
| WO2021233349A1 (zh) * | 2020-05-22 | 2021-11-25 | 南京明德新药研发有限公司 | 吡啶类衍生物及其应用 |
| CN114028377A (zh) * | 2021-11-29 | 2022-02-11 | 中国农业大学 | 咖啡醇的医药新用途 |
| EP4463169A4 (en) * | 2022-01-14 | 2025-10-29 | Dimerix Bioscience Pty Ltd | COMPOSITIONS COMPRISING A CHEMOKIN RECEPTOR PATHWAY INHIBITOR |
| CN115006516A (zh) * | 2022-06-14 | 2022-09-06 | 四川大学华西第二医院 | Cxcl13在制备治疗nafld相关的胰岛素抵抗和肝纤维化的药物中的应用 |
| CN115414363B (zh) * | 2022-10-08 | 2023-07-07 | 湖南师范大学 | 抗肝癌组合物和苯乙双胍在制备抗肝癌药物增敏剂的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1696910A4 (en) * | 2003-09-26 | 2009-12-09 | Smithkline Beecham Corp | COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS |
| CN107899012A (zh) * | 2011-01-11 | 2018-04-13 | 戴麦里克斯生物科学有限公司 | 联合疗法 |
| UA115807C2 (uk) * | 2013-05-15 | 2017-12-26 | Тобіра Терап'Ютикс, Інк. | Композиція (варіанти) ценікривіроку і спосіб її одержання та застосування (варіанти) |
| MX2016007066A (es) * | 2013-12-02 | 2016-09-08 | Oncomed Pharm Inc | Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. |
| CA2938406A1 (en) * | 2014-01-31 | 2015-08-06 | Janssen Pharmaceutica Nv | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
| RU2020119611A (ru) * | 2014-03-21 | 2020-06-29 | Тобира Терапьютикс, Инк. | Сенекривирок для лечения фиброза |
| EP3134074B1 (en) * | 2014-04-25 | 2020-06-03 | The Johns Hopkins University | Compositions comprising cyclodextrin incorporated collagen matrices for use in biomedical applications |
| CN106999593A (zh) * | 2014-09-12 | 2017-08-01 | 妥必徕疗治公司 | 用于纤维化治疗的赛尼克韦罗组合疗法 |
-
2016
- 2016-03-16 RU RU2018113437A patent/RU2018113437A/ru unknown
- 2016-03-16 EP EP16846982.3A patent/EP3349751A4/en not_active Withdrawn
- 2016-03-16 SG SG10202002323UA patent/SG10202002323UA/en unknown
- 2016-03-16 MX MX2018003179A patent/MX2018003179A/es unknown
- 2016-03-16 BR BR112018005163A patent/BR112018005163A2/pt not_active Application Discontinuation
- 2016-03-16 AU AU2016323468A patent/AU2016323468A1/en not_active Abandoned
- 2016-03-16 JP JP2018513847A patent/JP2018532720A/ja active Pending
- 2016-03-16 US US15/759,886 patent/US20180360846A1/en not_active Abandoned
- 2016-03-16 HK HK19100803.6A patent/HK1258396A1/zh unknown
- 2016-03-16 CA CA2998509A patent/CA2998509A1/en not_active Abandoned
- 2016-03-16 CN CN201680063405.7A patent/CN108289881A/zh active Pending
- 2016-03-16 WO PCT/US2016/022639 patent/WO2017048322A1/en not_active Ceased
- 2016-03-16 KR KR1020187010621A patent/KR20180088373A/ko not_active Ceased
-
2018
- 2018-03-11 IL IL258002A patent/IL258002A/en unknown
-
2020
- 2020-02-27 US US16/803,931 patent/US20200268768A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016323468A1 (en) | 2018-04-26 |
| RU2018113437A (ru) | 2019-10-17 |
| EP3349751A1 (en) | 2018-07-25 |
| JP2018532720A (ja) | 2018-11-08 |
| HK1258396A1 (zh) | 2019-11-08 |
| CN108289881A (zh) | 2018-07-17 |
| US20180360846A1 (en) | 2018-12-20 |
| KR20180088373A (ko) | 2018-08-03 |
| RU2018113437A3 (es) | 2019-10-17 |
| WO2017048322A1 (en) | 2017-03-23 |
| CA2998509A1 (en) | 2017-03-23 |
| EP3349751A4 (en) | 2019-05-22 |
| SG10202002323UA (en) | 2020-05-28 |
| IL258002A (en) | 2018-05-31 |
| US20200268768A1 (en) | 2020-08-27 |
| BR112018005163A2 (pt) | 2018-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003179A (es) | Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. | |
| MX2017003215A (es) | Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis. | |
| PH12021550119A1 (en) | Pyridin-2-one compounds useful as smarca2 antagonists | |
| PH12022551359A1 (en) | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | |
| PH12017500583B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| ZA202304064B (en) | Quinoline cgas antagonist compounds | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| NZ792518A (en) | Formulations for administration of eflornithine | |
| BR112017016428A2 (pt) | ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório? | |
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| MX2024013184A (es) | Metodos y composiciones para tratar apnea del sue?o | |
| EP3632469A3 (en) | Cyp2j2 antagonists in the treatment of pain | |
| AU2014287427B2 (en) | Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist | |
| AU2016407426A1 (en) | Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist | |
| MX2021000966A (es) | Piridopirimidinas como inhibidores del receptor de histamina h4. | |
| NZ738247A (en) | 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors | |
| MA39991A (fr) | Cénicriviroc pour le traitement de l'infection à vih-2 | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| WO2020065090A3 (en) | 5-ht7 antagonist for the treatment of dementia-associated tauopathies | |
| EA201990481A1 (ru) | Тройная комбинация обратных агонистов рецептора гистамина-3, ингибиторов ацетилхолинэстеразы и антагониста рецептора nmda | |
| NZ750150A (en) | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors | |
| MX2025007121A (es) | Compuestos antagonistas del receptor 2 de prostaglandina e2 (ep2) | |
| MX2014014813A (es) | Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño. |